LABA+ICS群と比較し、LAMA+LABA群の統合された主要評価項目の結果は以下の通りである：増悪、OR (95％CI ～、P = 、I 2 = 17％、低い質のエビデンス)；重篤な副作用、(95％CI ～、P = 、I 2 = 0％、中等度の質のエビデンス)；St. George's Respiratory Questionnaire (SGRQ)ベースラインからの変化、MD -(95％CI ～、P = 、I 2 = 71％、低い質のエビデンス)；トラフ一秒量ベースラインからの変化、MD (95％CI ～、P <、I 2 = 50%、中程度の質のエビデンス)。同様に二次評価項目の結果は以下の通りである：肺炎、OR (95％CI ～、P = 、I 2 = 0％、低い質のエビデンス)；全死亡、OR (95％CI ～、P = 、I 2 = 0％、低い質のエビデンス)、臨床的有意な最小変化量(4点)以上のSGRQベースラインからの改善、OR (95％CI ～、P = 、I 2 = 0％、中等度の質のエビデンス)。
Unfamiliarity with these newer inhalers has been the source of some recently reported errors. A patient discharged from the hospital on Spiriva HandiHaler was readmitted 3 days later after taking 3 Spiriva capsules by mouth each day. He was unaware that the capsule was to be placed in the device so its contents could be inhaled. A color-blind patient was unable to tell if the indicator window on a Tudorza Pressair inhaler was red or green. The window turns green when the inhaler is loaded with a dose and ready to use, and red when the dose has been completely inhaled. Errors have happened to healthcare providers, too. In the pharmacy, an order for Incruse Ellipta was mistaken as “Increase Ellipta,” and the pharmacist dispensed Breo Ellipta, the only “Ellipta” inhaler with which he was familiar.